Case-control study of aspirin use and risk of pancreatic cancer - PubMed (original) (raw)

Case-control study of aspirin use and risk of pancreatic cancer

Samantha A Streicher et al. Cancer Epidemiol Biomarkers Prev. 2014 Jul.

Abstract

Background: Pancreas-cancer prognosis is dismal, with 5-year survival less than 5%. Significant relationships between aspirin use and decreased pancreas-cancer incidence and mortality have been shown in four of 13 studies.

Methods: To evaluate further a possible association between aspirin use and risk of pancreatic cancer, we used data from a population-based Connecticut study conducted from January 2005 to August 2009, of 362 pancreas-cancer cases frequency matched to 690 randomly sampled controls.

Results: Overall, regular use of aspirin was associated with reduced risk of pancreatic cancer [odds ratio (OR), 0.52; 95% confidence interval (CI), 0.39-0.69]. Increments of decreasing risk of pancreatic cancer were observed for each year of low-dose or regular-dose aspirin use (OR, 0.94; 95% CI, 0.91-0.98 and OR, 0.98; 95% CI, 0.96-1.01, respectively) and for increasing years in the past that low-dose or regular-dose aspirin use had started (OR, 0.95; 95% CI, 0.92-0.99 and OR, 0.98; 95% CI, 0.96-1.00, respectively). Reduced risk of pancreatic cancer was seen in most categories of calendar time period of aspirin use, for both low-dose aspirin and regular-dose aspirin use. Relative to continuing use at the time of interview, termination of aspirin use within 2 years of interview was associated with increased risk of pancreatic cancer (OR, 3.24; 95% CI, 1.58-6.65).

Conclusions: Our results provide some support that a daily aspirin regimen may reduce risk of developing pancreatic cancer.

Impact: Long-term aspirin use has benefits for both cardiovascular disease and cancer, but appreciable bleeding complications that necessitate risk-benefit analysis for individual applications.

©2014 American Association for Cancer Research.

PubMed Disclaimer

Conflict of interest statement

Disclosures: There were no apparent or real conflicts of interest for any of the authors.

References

    1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
    1. Yeo TP, Lowenfels AB. Demographics and epidemiology of pancreatic cancer. Cancer J. 2012;18:477–84. - PubMed
    1. Eldridge RC, Gapstur SM, Newton CC, Goodman M, Patel AV, Jacobs EJ. Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2011;20:691–8. - PubMed
    1. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002;94:1168–71. - PubMed
    1. Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res. 2011;4:1835–41. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources